Dalfampridine and Gait in Spinocerebellar Ataxias

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Investigators expect there will be improvement in walking speed and steadiness after taking Dalfampridine, thereby improving activities of daily living and enhancing social and occupational functions for patients with spinocerebellar ataxia.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Florida
• Collaborator: Acorda Therapeutics
• Treatments: 4-Aminopyridine

Criteria

Inclusion Criteria:

• Individuals at age 18 years or older.

• Individuals who can provide the informed consent

• Genetic confirmed definite spinocerebellar ataxias (SCA)

• Able to complete two trials of the timed 25-foot walk at screening

Exclusion Criteria:

• Patients who has severe ataxia and unable to ambulate.

• Any orthopedic condition that would affect motor performance.

• Patients with secondary ataxia from general medical disorders

• Individuals who have major psychiatric disorders that prevents compliance

• History of epilepsy

• Patients with active drug or alcohol use or dependence that would interfere with adherence to study requirements

• Inability or unwillingness of subject or legal guardian/representative to give written informed consent.